Purple Biotech Ltd.

0.39 USD
+0.01 (+2.10%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Purple Biotech Ltd. stock is down -27.96% since 30 days ago. The next earnings date is Aug 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 July’s closed higher than June. 100% of analysts rate it a buy.

About Purple Biotech Ltd.

Purple Biotech Ltd. focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors. NT219, a small molecule that targets insulin receptor substrate substrate substrate 1 and 2, and signal transducer and activator of transcription, is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors.